Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

05-04	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI
05-04	Stallergenes Greer Ltd Appoints Andreas Christian Amrein as Director on April 30, 2026	CI

Market Cap	724M 828M 670M 614M 1.16B 79.82B 1.18B 7.99B 3.14B 38.98B 3.11B 3.04B 135B	P/E 2022	-369x	P/E 2023	-161x
Enterprise Value	748M 856M 692M 635M 1.2B 82.5B 1.22B 8.25B 3.24B 40.29B 3.22B 3.14B 139B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	-	Yield 2022 *	-	Yield 2023	-

05-04	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI
05-04	Stallergenes Greer Ltd Appoints Andreas Christian Amrein as Director on April 30, 2026	CI
25-10-06	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-07	Stallergenes Greer Ltd Announces Termination of Nunzio Michele Antonelli as Director	CI
25-01-09	European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers with Confirmed Peanut Allergy	CI
24-09-30	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-07-11	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
23-05-25	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI
22-05-05	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-01-17	Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	CI
21-10-26	Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery	CI
21-07-09	Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy	CI
21-06-24	Stallergenes Greer Ltd Announces Alustal®, Subcutaneous Allergen Immunotherapy Treatment Now Available	CI

18-01-25	Stallergenes Greer : comments on share price movement	PU
17-10-04	Stallergenes Greer : 04/10/2017 - Director/PDMR Shareholding. Released October 4, 2017	PU
17-10-03	Stallergenes Greer : 03/10/2017 - Director/PDMR Shareholding	PU
17-06-19	Stallergenes Greer : First real-world evidence shows long term benefits of sublingual immunotherapy to control allergic rhinitis and potentially prevent allergic asthma	PU
17-05-03	Stallergenes Greer : NOTIFICATION TO SHAREHOLDERS OF ANNUAL GENERAL MEETING ON 8 JUNE 2017	PU

Stallergenes Greer Stock

Stocks

STAGR

GB00BZ21RF93

Pharmaceuticals

Valuation: Stallergenes Greer

Latest news : Stallergenes Greer

Press Releases: Stallergenes Greer

News in other languages: Stallergenes Greer

Managers and Directors: Stallergenes Greer

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

23-11-06	AB Science : Le secteur pharmaceutique signe un accord de branche sur la transition écologique
19-05-17	Stallergenes Greer : radiation du titre ce jour
19-05-17	Stallergenes Greer : fin de partie à la Bourse de Paris
19-05-14	EN DIRECT DES MARCHES : EDF, Vinci, Ipsen, Europlasma, Erytech, Bayer, Volkswagen...
19-05-14	Trump, la carotte après le bâton

Manager	Title	Age	Since
Andreas Amrein CEO	Chief Executive Officer	-	2025-03-31
Amer Jaber COO	Chief Operating Officer	-	2018-12-31
Daniel Smith CTO	Chief Tech/Sci/R&D Officer	-	2016-04-10

Director	Title	Age	Since
Francesco Pietro Crispino BRD	Director/Board Member	-	2019-05-06
Nicola Lamacchia BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STALLERGENES GREER	-.--%	+0.14%	-	-	0
MERCK & CO., INC.	+3.25%	+2.05%	+54.83%	+18.90%	315B
MERCK KGAA	-1.53%	-1.18%	+24.90%	-7.73%	68.62B
HALOZYME THERAPEUTICS, INC.	+2.27%	-1.37%	+33.67%	+102.88%	9.2B
KYOWA KIRIN CO., LTD.	-0.45%	-0.28%	+3.84%	-1.48%	8.52B
BETTA PHARMACEUTICALS CO., LTD.	-3.05%	+0.42%	+6.92%	+28.13%	4.04B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-1.00%	-18.56%	+3.79%	4.2B
YUHAN CORPORATION	+1.87%	+5.04%	-37.18%	+24.94%	3.56B
SUPERNUS PHARMACEUTICALS, INC.	+1.01%	-1.11%	+43.82%	+60.54%	2.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.81%	+7.81%	+12.16%	-16.29%	2.26B
Average	+0.49%	-0.68%	+13.82%	+23.74%	41.84B
Weighted average by Cap.	+2.37%	-1.76%	+46.13%	+16.04%

	2022	2023
Net sales	-	-
Net income	-1.96M -2.24M -1.81M -1.66M -3.15M -216M -3.21M -21.64M -8.5M -106M -8.43M -8.24M -365M	-4.51M -5.16M -4.17M -3.82M -7.24M -497M -7.36M -49.7M -19.52M -243M -19.36M -18.93M -837M
Net Debt	18.77M 21.47M 17.36M 15.93M 30.14M 2.07B 30.67M 207M 81.31M 1.01B 80.63M 78.86M 3.49B	24.35M 27.86M 22.52M 20.66M 39.11M 2.68B 39.79M 269M 105M 1.31B 105M 102M 4.53B